As the official Canadian provider, we offer the Galleri test at our Toronto, Oakville, and Collingwood locations. For those in other areas, we now also offer the option to complete the blood draw through an in-home visit or at a local blood collection centre across Ontario.
However you complete your Galleri blood draw, Medcan’s clinical team will guide you through the testing process and help you navigate your results.
The Galleri test by GRAIL sets the standard for multi-cancer early detection and is ideal for those who are seeking a more comprehensive proactive approach to cancer screening.
Through a single blood draw, this test screens for 50+ cancer types, including aggressive types like pancreatic and ovarian, before they become symptomatic*. This maximizes the opportunity for early diagnosis, when treatment can be most effective.
Medcan is proud to be the exclusive provider of the Galleri test in Ontario.
Medcan is here to support you every step of the way.
Request more information using the button below and a member of our team will contact you to help answer any questions you may have and facilitate your booking.
Call us at 416-350-5222 and speak to a member of our team who will help facilitate your booking.
Curious about our services, or ready to start experiencing the benefits of being a Medcan client?
Disclaimers and Resources:
*The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. 1 in 100 can expect to receive a CSD result, and approximately 60% of these individuals will receive a confirmed cancer diagnosis. The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).
Important Safety Information: The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur.
Lab / Test information: The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. This test is not Health Canada or FDA approved, and has not been endorsed by any professional medical societies at this time. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Galleri is a registered trademark of GRAIL, Inc.